Fluorine-Containing Chiral Drugs

Chiral Drugs: Chemistry and Biological Action

Volumn , Issue , 2011, Pages 195-252

  Qiu, Xiao Long ^a   Yue, Xuyi ^a   Qing, Feng Ling ^a,b  

^a SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^b DONGHUA UNIVERSITY   (China)

Author keywords

Fluorine containing chiral drugs fluorine, one of the most abundant elements on Earth; Organofluorine compounds, and synthetic methods asymmetric electrophilic fluorination, naturally occurring fluorinated organic compounds; Simple, direct one pot organocatalytic approach formation of optically active propargylic fluorides

Indexed keywords

EID: 84881291128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075647.ch5     Document Type: Chapter

References (146)

1. O'Hagan, D., Harper, D. B. (1999). Fluorine-containing natural products. J. Fluorine Chem. 100, 127-133.
2. Banks, R., Smart, B., Tatlow, J. (1994). Organofluorine Chemistry: Principles and Commercial Applications. New York: Plenum Press.
3. Ojima, I., McCarthy, J., Welch, J. (1996). Biomedical Frontiers of Fluorine Chemistry. Washington, DC: American Chemical Society.
4. Soloshonok, V. A. (2005). Fluorine-Containing Synthons. Washington, DC: American Chemical Society.
5. Fried, J., Sabo, E. F. (1953). Synthesis of 9α-ahydroxycorticosterone and its 9α-halo derivatives from 11-epi-9α-ahydroxycorticosterone. J. Am. Chem. Soc. 75, 2273-2274.
6. Heidelberger, C., Chaudhuri, N. K., Danneberg, P., Mooren, D., Griesbach, L., Duschinsky, R., Schnitzer, R., Pleven, E., Scheiner, J. (1957). Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663-666.
7. Bravo, P., Resnati, G., Angeli, P., Frigerio, M., Viani, F., Arnone, A., Marucci, G., Cantalamessa, F. (1992). Synthesis and pharmacological evaluation of enantiomerically pure 4-deoxy-4-fluoromuscarines. J. Medicinal Chem. 35, 3102-3110.
8. Lu, S. F., Herbert, B., Haufe, G., Laue, K. W., Padgett, W. L., Oshunleti, O., Daly, J. W., Kirk, K. L. (2000). Syntheses of (R)-and (S)-2-and 6-fluoronorepinephrine and (R)-and (S)-2-and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities. J. Medicinal Chem. 43, 1611-1619.
9. Tewson, T. J., Stekhova, S., Kinsey, B., Chen, L., Wiens, L., Barber, R. (1999). Synthesis and biodistribution of R-and S-isomers of [18F]-fluoropropranolol, a lipophilic ligand for the ß-adrenergic receptor. Nucl. Med. Biol. 26, 891-896.
10. Park, B. K., Kitteringham, N. R. (1994). Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab. Rev. 26, 43.
11. Bondi, A. (1964). Van Der Waals volumes + radii. J. Phys. Chem. 68, 441-451.
12. Lide, D. R. (2009). Handbook of Chemistry and Physics. New York: CRC.
13. Liebman, J. F., Greenberg, A. (1986). Molecular Structure and Energetics: Vol.3. Studies of Organic Molecules. Weinheim: VCH.
14. de Riggi, I., Virgili, A., de Moragas, M., Jaime, C. (1995). Restricted rotation and NOE transfer: a conformational study of some substituted (9-anthryl)carbinol derivatives. J. Org. Chem. 60, 27-31.
15. Harper, D. B., O'Hagan, D. (1994). The fluorinated natural products. Natural Product Rep. 11, 123-133.
16. Lauble, H., Kennedy, M. C., Emptage, M. H., Beinert, H., Stout, C. D. (1996). The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Proc. Natl. Acad. Sci. U. S. A. 93, 13699-13703.
17. Peters, R., Wakelin, R. W., Buffa, P. (1953). Biochemistry of fluoroacetate poisoning the isolation and some properties of the fluorotricarboxylic acid inhibitor of citrate metabolism. Proc. R. Soc. B Biol. Sci. 140, 497-506.
18. Tamura, T., Wada, M., Esaki, N., Soda, K. (1995). Synthesis of fluoroacetate from fluoride, glycerol, and ß-hydroxypyruvate by Streptomyces cattleya. J. Bacteriol. 177, 2265-2269.
19. Marais, J. C. S. (1943). The isolation of the toxic principle "K cymonate" from "Gifblaar", Dichapetalum cymosum. Onderstepoort J. Vet. Res. 18, 203.
20. Marais, J. S. C. (1944). Monofluoroacetic acid, the toxic principle of &Gifblaar" Dichapetalum cymosum (Hook) Engl. Onderstepoort J. Vet. Res. 20, 67-73.
21. Cruciani, G., Carosati, E., De Boeck, B., Ethirajulu, K., Mackie, C., Howe, T., Vianello, R. (2005). MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. Medicinal Chem. 48, 6970-6979.
22. Clader, J. W. (2004). The discovery of ezetimibe: a view from outside the receptor. J. Medicinal Chem. 47, 1-9.
23. Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., Rogers, R. S., Rogier, D. J., Yu, S. S., Anderson, G. D., Burton, E. G., Cogburn, J. N., Gregory, S. A., Koboldt, C. M., Perkins, W. E., Seibert, K., Veenhuizen, A. W., Zhang, Y. Y., Isakson, P. C. (1997). Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Medicinal Chem. 40, 1347-1365.
24. DeLuca, H. F., Schnoes, H. K. (1984). Vitamin D: metabolism and mechanism of action. In Annual Reports in Medicinal Chemistry, Denis, M. B. Ed. Academic Press, vol. 19, p. 179-190.
25. Tanaka, Y., DeLuca, H. F., Kobayashi, Y., Ikekawa, N. (1984). 26, 26, 26, 27, 27, 27-Hexafluoro-1, 25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1, 25-dihydroxyvitamin D3. Arch. Biochem. Biophys. 229, 348-354.
26. Dear, G. J., Ismail, I. M., Mutch, P. J., Plumb, R. S., Davies, L. H., Sweatman, B. C. (2000). Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS. Xenobiotica 30, 407-426.
27. Koerts, J., Soffers, A. E. M. F., Vervoort, J., De Jager, A., Rietjens, I. M. C. M. (1998). Occurrence of the NIH shift upon the cytochrome P450-catalyzed in vivo and in vitro aromatic ring hydroxylation of fluorobenzenes. Chem.Res. Toxicol. 11, 503-512.
28. Park, B. K., Kitteringham, N. R., O'Neill, P. M. (2001). Metabolism of fluorinecontaining drugs. Annu. Rev. Pharmacol. Toxicol. 41, 443-470.
29. Abraham, M. H., Grellier, P. L., Prior, D. V., Duce, P. P., Morris, J. J., Taylor, P. J. (1989). Hydrogen bonding. Part 7. A scale of solute hydrogen-bond acidity based on log K values for complexation in tetrachloromethane. J. Chem. Soc. Perkin Trans. 2, 699-711.
30. Schlosser, M. (1998). Parametrization of substituents: effects of fluorine and other heteroatoms on OH, NH, and CH acidities. Angew. Chem. Int. Ed. 37, 1496-1513.
31. Smart, B. E. (2001). Fluorine substituent effects (on bioactivity). J. Fluorine Chem. 109, 3-11.
32. Speight, J. G. (2005). Lange's Handbook of Chemistry. New York: McGraw-Hill.
33. Morgenthaler, M., Schweizer, E., Hoffmann-Röder, A., Benini, F., Martin, Rainer E., Jaeschke, G., Wagner, B., Fischer, H., Bendels, S., Zimmerli, D., Schneider, J., Diederich, F., Kansy, M., Müller, K. (2007). Predicting and tuning physicochemical properties in lead optimization: amine basicities. Chem. Med. Chem. 2, 1100-1115.
34. Maren, T. H., Conroy, C. W. (1993). A new class of carbonic anhydrase inhibitor. J. Biol. Chem. 268, 26233-26239.
35. Kim, C. Y., Chang, J. S., Doyon, J. B., Baird, T. T., Fierke, C. A., Jain, A., Christianson, D. W. (2000). Contribution of fluorine to protein-ligand affinity in the binding of fluoroaromatic inhibitors to carbonic anhydrase II. J. Am. Chem. Soc. 122, 12125-12134.
36. Mandell, L. A., Ball, P., Tillotson, G. (2001). Antimicrobial safety and tolerability: differences and dilemmas. Clin. Infect. Dis. 32, S72-S79.
37. Port, R. E., Wolf, W. (2003). Noninvasive methods to study drug distribution. Invest. New Drugs 21, 157-168.
38. Prusoff, W. H. (1959). Synthesis and biological activities of iododeoxyuridine, an analog of thymidine Biochim. Biophys. Acta 32, 295-296.
39. Watanabe, K. A., Reichman, U., Hirota, K., Lopez, C., Fox, J. J. (1979). Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J. Medicinal Chem. 22, 21-24.
40. Marquez, V. E., Tseng, C. K. H., Kelley, J. A., Mitsuya, H., Broder, S., Roth, J. S., Driscoll, J. S. (1987). 2', 3'-Dideoxy-2'-fluoro-ara-a. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36, 2719-2722.
41. Okabe, M., Sun, R. C., Zenchoff, G. B. (1991). Synthesis of 1-(2, 3-dideoxy-2-fluoro-beta-d-threo-pentofuranosyl)cytosine (F-ddC). A promising agent for the treatment of acquired immune deficiency syndrome. J. Org. Chem. 56, 4392-4397.
42. Böhm, H. J., Banner, D., Bendels, S., Kansy, M., Kuhn, B., Müller, K., Obst-Sander, U., Stahl, M. (2004). Fluorine in medicinal chemistry. Chem. Bio. Chem. 5, 637-643.
43. Böhm, H. J., Schneider, G. (2003). Protein-Ligand Interactions: From Molecular Recognition to Drug Design. Weinheim: Wiley-VCH.
44. Ganguly, T., Mal, S., Mukherjee, S. (1983). Hydrogen bonding ability of fluoroalcohols. Spectrochim. Acta A Mol. Spectrosc. 39, 657-660.
45. Wildman, S. A., Crippen, G. M. (1999). Prediction of physicochemical parameters by atomic contributions. J. Chem. Inf. Comput. Sci. 39, 868-873.
46. Yamazaki, T., Taguchi, T., Ojima, I. (2009). Unique Properties of Fluorine and Their Relevance to Medicinal Chemistry and Chemical Biology in Fluorine in Medicinal Chemistry and Chemical Biology. New York: Wiley.
47. Müller, K., Faeh, C., Diederich, F. (2007). Fluorine in pharmaceuticals: looking beyond intuition. Science 317, 1881-1886.
48. Paulini, R., Müller, K., Diederich, F. (2005). Orthogonal multipolar interactions in structural chemistry and biology. Angew. Chem. Int. Ed. 44, 1788-1805.
49. Parlow, J. J., Kurumbail, R. G., Stegeman, R. A., Stevens, A. M., Stallings, W. C., South, M. S. (2003). Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex. Bioorg. Medicinal Chem. Lett. 13, 3721-3725.
50. Parlow, J. J., Kurumbail, R. G., Stegeman, R. A., Stevens, A. M., Stallings, W. C., South, M. S. (2003). Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors. J. Medicinal Chem. 46, 4696-4701.
51. Parlow, J. J., Stevens, A. M., Stegeman, R. A., Stallings, W. C., Kurumbail, R. G., South, M. S. (2003). Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. J. Medicinal Chem. 46, 4297-4312.
52. Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisá, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., Goldsmith, E. J. (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128.
53. Hughes, D. L., Sieker, L. C., Bieth, J., Dimicoli, J. L. (1982). Crystallographic study of the binding of a trifluoroacetyl dipeptide anilide inhibitor with elastase. J. Mol. Biol. 162, 645-658.
54. Olsen, J. A., Banner, D. W., Seiler, P., Wagner, B., Tschopp, T., Obst-Sander, U., Kansy, M., Müller, K., Diederich, F. (2004). Fluorine interactions at the thrombin active site: protein backbone fragments H-C-α-C = O comprise a favorable C-F envionment and interaction of C-F with electrophiles. Chem. Bio. Chem. 5, 666-675.
55. Istvan, E. S., Deisenhofer, J. (2001). Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164.
56. Kertesz, D. J., Marx, M. (1986). Thiol esters from steroid 17beta.-carboxylic acids: carboxylate activation and internal participation by 17alpha-acylates. J. Org. Chem. 51, 2315-2328.
57. Barkalow, J., Chamberlin, S. A., Cooper, A. J., Hossain, A., Hufnagel, J. J., Langridge, D. C. (2001). Method for the preparation of fluticasone and related 17 beta eta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods. PCT Int. Appl. WO2001062722.
58. Chu, D., Zhang, D. (2007). Method for the preparation of fluticasone propionate. PCT Int. Appl. WO2007012228.
59. Marcellin, P., Mommeja-Marin, H., Sacks, S. L., Lau, G. K. K., Sereni, D., Bronowicki, J. P., Conway, B., Trepo, C., Blum, M. R., Yoo, B. C., Mondou, E., Sorbel, J., Snow, A., Rousseau, F., Lee, H. S. (2004). A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40, 140-148.
60. Yoo, B. C., Kim, J. H., Kim, T. H., Koh, K. C., Um, S. H., Kim, Y. S., Lee, K. S., Han, B. H., Chon, C. Y., Han, J. Y., Ryu, S. H., Kim, H. C., Byun, K. S., Hwang, S. G., Kim, B. I., Cho, M., Yoo, K., Lee, H. J., Hwang, J. S., Kim, Y. S., Lee, Y. S., Choi, S. K., Lee, Y. J., Yang, J. M., Park, J.W., Lee, M. S., Kim, D. G., Chung, Y. H., Cho, S. H., Choi, J. Y., Kweon, Y. O., Lee, H. Y., Jeong, S. H., Yoo, H. W., Lee, H. S. (2007). Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 46, 1041-1048.
61. Ma, T., Lin, J. S., Newton, M. G., Cheng, Y. C., Chu, C. K. (1997). Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-ß-l-arabinofuranosyl)purine Nucleosides. J. Medicinal Chem. 40, 2750-2754.
62. Ma, T., Pai, S. B., Zhu, Y. L., Lin, J. S., Shanmuganathan, K., Du, J., Wang, C., Kim, H., Newton, M. G., Cheng, Y. C., Chu, C. K. (1996). Structure-activity relationships of 1-(2-deoxy-2-fluoro-ß-l-arabino-furanosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J. Medicinal Chem. 39, 2835-2843.
63. Sznaidman, M. L., Almond, M. R., Pesyan, A. (2002). New synthesis of l-fmau from l-arabinose. Nucleosides Nucleotides Nucl. Acids 21, 155-163.
64. Chilman-Blair, K., Mealy, N. E., Castaner, J. (2004). Clofarabine. Treatment of acute leukemia. Drugs Future 29, 112-120.
65. Jeha, S., Razzouk, B., Rytting, M., Rheingold, S., Albano, E., Kadota, R., Luchtman-Jones, L., Bomgaars, L., Gaynon, P., Goldman, S., Ritchey, K., Arceci, R., Altman, A., Stine, K., Steinherz, L., Steinherz, P. (2009). Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J. Clin. Oncol. 27, 4392-4397.
66. Reichman, U., Watanabe, K. A., Fox, J. J. (1975). A practical synthesis of 2-deoxy-2-fluoro-arabinofuranose derivatives. Carbohydrate Res. 42, 233-240.
67. Bauta, W. E., Schulmeier, B. E., Burke, B., Puente, J. F., Cantrell, W. R., Lovett, D., Goebel, J., Anderson, B., Ionescu, D., Guo, R. (2004). A new process for antineoplastic agent clofarabine II. Org. Process Res. Dev. 8, 889-896.
68. Anderson, B. G., Bauta, W. E., Cantrell, J. W. R., Engles, T., Lovett, D. P. (2008). Isolation, synthesis, and characterization of impurities and degradants from the clofarabine process. Org. Process Res. Dev. 12, 1229-1237.
69. Langen, P. (1975). Antimetabolites of Nucleic Acid Metabolism: The Biochemical Basis of Their Action, with Special Reference to Their Application in Cancer Therapy. New York: Gordon and Breach.
70. Hoshi, A., Castañer, J. (1994). Alovudine. Antiviral, Anti-HIV. Drugs Future 19, 221.
71. Etzold, G., Hintsche, R., Kowollik, G., Langen, P. (1971). Nucleoside von fluorzuckern. VI: Synthese und reaktivität von 3'-fluor-und 3'-chlor-3'-desoxy-thymidin. Tetrahedron 27, 2463-2472.
72. Kowollik, G., Janta-Lipinski, M., Gaertner, K., Langen, P., Etzold, G. (1973). Nucleoside von Fluorzuckern. XII. Ein neuer Zugang zu 1-(2, 3-Didesoxy-3-fluor-beta-d-ribofuranosyl)-pyrimidinen. J. Praktische Chemie 315, 895-900.
73. Watanabe, K. A., Harada, K., Zeidler, J., Matulic-Adamic, J., Takahashi, K., Ren, W. Y., Cheng, L. C., Fox, J. J., Chou, T. C. (1990). Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2', 3'-dideoxycytidine (DDC). J. Medicinal Chem. 33, 2145-2150.
74. Hewawasam, P., Gribkoff, V. K., Pendri, Y., Dworetzky, S. I., Meanwell, N. A., Martinez, E., Boissard, C. G., Post-Munson, D. J., Trojnacki, J. T., Yeleswaram, K., Pajor, L. M., Knipe, J., Gao, Q., Perrone, R., Starrett, J. E. (2002). The synthesis and characterization of BMS-204352 (MaxiPost™) and related 3-fluorooxindoles as openers of maxi-K potassium channels. Bioorg. Medicinal Chem. Lett. 12, 1023-1026.
75. de Angelis, L. (1987). Flurithromycin. Drugs Future 12, 214.
76. Naber, K. G., Adam, D. (1998). The classification of fluoroquinolones. Chemother. J. 7, 66-68.
77. Kimura, Y., Atarashi, S., Kawakami, K., Sato, K., Hayakawa, I. (1994). (Fluorocyclopropyl)quinolones. 2. Synthesis and stereochemical structureactivity relationships of chiral 7-(7-amino-5-azaspiro [2.4] heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. J. Medicinal Chem. 37, 3344-3352.
78. Prous, J., Graul, A., Castaner, J. (1994). DU-6859 (sitafloxacin). Drugs Future 19, 827-834.
79. Andreasen, N. C. (1994). Schizophrenia: from Mind to Molecule. Washington, DC: American Psychiatric Press.
80. Meltzer, H. Y., Matsubara, S., Lee, J. C. (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Therapeut. 251, 238-246.
81. Rowley, M., Hallett, D. J., Goodacre, S., Moyes, C., Crawforth, J., Sparey, T. J., Patel, S., Marwood, R., Patel, S., Thomas, S., Hitzel, L., O'Connor, D., Szeto, N., Castro, J. L., Hutson, P. H., MacLeod, A. M. (2001). 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT2A receptor antagonists. J. Medicinal Chem. 44, 1603-1614.
82. O'Neill, M. J., Murray, T. K., Clay, M. P., Lindstrom, T., Yang, C. R., Nisenbaum, E. S. (2005). LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev. 11, 77-96.
83. Murray, T. K., Whalley, K., Robinson, C. S., Ward, M. A., Hicks, C. A., Lodge, D., Vandergriff, J. L., Baumbarger, P., Siuda, E., Gates, M., Ogden, A. M., Skolnick, P., Zimmerman, D. M., Nisenbaum, E. S., Bleakman, D., O'Neill, M. J. (2003). LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Therapeut. 306, 752-762.
84. Ryder, J. W., Falcone, J. F., Manro, J. R., Svensson, K. A., Merchant, K. M. (2006). Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J. Pharmacol. Exp. Therapeut. 319, 293-298.
85. O'Neill, M. J., Bleakman, D., Zimmerman, D. M., Nisenbaum, E. S. (2004). AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3, 181-194.
86. O'Neill, M. J., Witkin, J. M. (2007). AMPA receptor potentiators: application for depression and Parkinson's disease Curr. Drug Targets 8, 603-620.
87. Magnus, N. A., Aikins, J. A., Cronin, J. S., Diseroad, W. D., Hargis, A. D., LeTourneau, M. E., Parker, B. E., Reutzel-Edens, S. M., Schafer, J. P., Staszak, M. A., Stephenson, G. A., Tameze, S. L., Zollars, L. M. H. (2005). Diastereomeric salt resolution based synthesis of LY503430, an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) potentiator. Org. Process Res. Dev. 9, 621-628.
88. Nagengast, F. M., Grubben, M. J. A. L., van Munster, I. P. (1995). Role of bile acids in colorectal carcinogenesis. Eur. J. Cancer 31, 1067-1070.
89. Gibson, J. C., Capuano, L. R. (1997). Prevention and Treatment of Colorectal Cancer by 6-Fluoroursodeoxychlolic Acid. WO 97/44043.
90. Konigsberger, K., Chen, G. P., Vivelo, J., Lee, G., Fitt, J., McKenna, J., Jenson, T., Prasad, K., Repic, O. (2002). An expedient synthesis of 6α-fluoroursodeoxycholic acid. Org. Process Res. Dev. 6, 665-669.
91. Chung, M. K., Kim, J. C., Roh, J. K. (1995). Teratogenic effects of DA-125, a new anthracycline anticancer agent, in rats. Reprod. Toxicol. 9, 159-164.
92. Lee, M. G., Yang, J. (1996). DA-125. Antineoplastic agent. Drugs Future 21, 782.
93. Mohedano, N., Sanchez-Rovira, P., Medina, B., Flores-Gonzalez, E., Moreno, M. A., Fernandez, M., Lozano, A. (1997). Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC). Lung Cancer 18, 43.
94. Colomer, R. (2005). Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer. Women's Health 1, 323-329.
95. Moen, M. D., Wellington, K. (2005). Gemcitabine: in combination with paclitaxel in the first-line treatment of metastatic breast cancer. Am. J. Cancer 4, 327-333.
96. Tomao, S., Romiti, A., Tomao, F., Di Seri, M., Caprio, G., Spinelli, G., Terzoli, E., Frati, L. (2006). A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC Cancer 6, 137.
97. Oldfield, V., Wellington, K. (2005). Gemcitabine: in combination with carboplatin in the treatment of recurrent ovarian cancer. Am. J. Cancer 4, 337-344.
98. Pfisterer, J., Vergote, I., Bois, A. D., Eisenhauer, E. (2005). Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Intl. J. Gynecol. Cancer 15, 36-41.
99. Hertel, L. W., Kroin, J. S., Misner, J. W., Tustin, J. M. (1988). Synthesis of 2-deoxy-2, 2-difluoro-d-ribose and 2-deoxy-2, 2'-difluoro-d-ribofuranosyl nucleosides. J. Org. Chem. 53, 2406-2409.
100. Chou, T. S., Heath, P. C., Patterson, L. E., Poteet, L. M., Lakin, R. E., Hunt, A. H. (1992). Stereospecific synthesis of 2-deoxy-2, 2-difluororibonolactone and its use in the preparation of 2'-deoxy-2', 2'-difluoro-ß-d-ribofuranosyl pyrimidine nucleosides: the key role of selective crystallization. Synthesis, 565-570.
101. Sorbera, L. A., Casta ner, J., Mealy, N. E. (2004). Lubiprostone. Treatment of constipation, treatment of irritable bowel syndrome, treatment of postoperative ileus, CIC-2 channel activator. Drugs Future 29, 336.
102. Ueno, R. (2001). Endothelin antagonist. US6197821.
103. Choudhury, A., Moore, J. R., Pierce, M. E., Fortunak, J. M., Valvis, I., Confalone, P. N. (2003). In situ recycling of chiral ligand and surplus nucleophile for a noncatalytic reaction: amplification of process throughput in the asymmetric addition step of efavirenz (DMP 266). Org. Process Res. Dev. 7, 324-328.
104. Rabasseda, X., Sorbera, L. A., Casta ner, J. (1999). Befloxatone. Antidepressant, MAO-A inhibitor. Drugs Future 24, 1057.
105. Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J. P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., Li, C. S., Massé, F., McKay, D. J., Nicoll-Griffith, D. A., Oballa, R. M., Palmer, J. T., Percival, M. D., Riendeau, D., Robichaud, J., Rodan, G. A., Rodan, S. B., Seto, C., Thérien, M., Truong, V. L., Venuti, M. C., Wesolowski, G., Young, R. N., Zamboni, R., Black, W. C. (2008). The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Medicinal Chem. Lett. 18, 923-928.
106. O'Shea, P. D., Chen, C. Y., Gauvreau, D., Gosselin, F., Hughes, G., Nadeau, C., Volante, R. P. (2009). a practical enantioselective synthesis of odanacatib, a potent cathepsin K Inhibitor, via triflate displacement of an a-trifluoromethylbenzyl triflate. J. Org. Chem. 74, 1605-1610.
107. Qing, F. L., Qiu, X. L. (2007). Fluoroorganic Chemistry. Beijing: Science Press.
108. Jiang, Y., Liu, Z. (2009). Progresses in enantioselective electrophilic fluorinations. Chin. J. Org. Chem. 29, 1362-1370.
109. Cahard, D., Xu, X., Couve-Bonnaire, S., Pannecoucke, X. (2010). Fluorine & chirality: how to create a nonracemic stereogenic carbon-fluorine centre? Chem. Soc. Rev. 39, 558-568.
110. Rozen, S. (1988). Elemental fluorine as a legitimate reagent for selective fluorination of organic-compounds. Acc. Chem. Res. 21, 307-312.
111. Rozen, S. (1996). Elemental fluorine: not only for fluoroorganic chemistry. Acc. Chem. Res. 29, 243-248.
112. Barton, D. H. R., Godinho, L. S., Hesse, R. H., Pechet, M. M. (1968). Organic reactions of fluoroxy-compounds-electrophilic fluorination of activated olefins. Chem. Commun. 804.
113. Barton, D. H. R., Ganguly, A. K., Hesse, R. H., Loo, S. N., Pechet, M. M. (1968). Organic reactions of fluoroxy-compounds-electrophilic fluorination of aromatic rings. Chem. Commun. 806.
114. Schack, C. J. Christe, K. O. (1979). Reactions of fluorine perchlorate with fluorocarbons and the polarity of the O-F bond in covalent hypofluorites. Inorg. Chem. 18, 2619-2620.
115. Tius, M. A. (1995). Xenon difluoride in synthesis. Tetrahedron 51, 6605-6634.
116. Schmutzler, R. (1968). Nitrogen oxide fluorides. Angew. Chem. Int. Engl. 7, 440-455.
117. Rozen, S. (1996). Selective fluorinations by reagents containing the OF group. Chem. Rev. 96, 1717-1736.
118. Differding, E., Lang, R. W. (1988). New fluorinating reagents. 1. The 1st enantioselective fluorination reaction. Tetrahedron Lett. 29, 6087-6090.
119. Davis, F. A., Zhou, P., Murphy, C. K., Sundarababu, G., Qi, H. Y., Han, W., Przeslawski, R. M., Chen, B. C., Carrol, P. J. (1998). Asymmetric fluorination of enolates with nonracemic N-fluoro-2, 10-camphorsultams. J. Org. Chem. 63, 2273-2280.
120. Takeuchi, Y., Suzuki, T., Satoh, A., Shiragami, T., Shibata, N. (1999). Nfluoro-3-cyclohexyl-3-methyl-2, 3-dihydrobenzo [1, 2-d] isothiazole 1, 1-dioxide: an efficient agent for electrophilic asymmetric fluorination of enolates. J. Org. Chem. 64, 5708-5711.
121. Shibata, N., Liu, Z. P., Takeuchi, Y. (2000). Novel enantioselective fluorinating agents. (R)-and (S)-N-fluoro-3-tert-butyl-7-niitro-3, 4-dihydro-2H-benzo[e][1, 2]thiazine 1, 1-dioxides. Chem. Pharm. Bull. 48, 1954-1958.
122. Liu, Z. P., Shibata, N., Takeuchi, Y. (2000). Novel methods for the facile construction of 3, 3-disubstituted and 3, 3-spiro-2H, 4H-benzo[e] 1, 2-thiazine-1, 1-diones: synthesis of (11S, 12R, 14R)-2-fluoro-14-methyl-11(methylethyl) spiro [4H-benzo[e]-1, 2-thiazine-3, 2'-cyclohexane]-1, 1-dione, an agent for the electrophilic asymmetric fluorination of aryl ketone enolates. J. Org. Chem. 65, 7583-7587.
123. Sun, H. M., Liu, Z. P., Tang, L. Q. (2008). Synthesis of novel chiral fluorinating agents. (+)-and (-)-N-fluoro-3-methyl-3-(4-methylphenyl)-2H-benzo[e][1, 2] thiazine-1, 1, 4-triones. Chin. Chem. Lett. 19, 907-910.
124. Shibata, N., Suzuki, E., Takeuchi, Y. (2000). A fundamentally new approach to enantioselective fluorination based on cinchona alkaloid derivatives/selectfluor combination. J. Am. Chem. Soc. 122, 10728-10729.
125. Cahard, D., Audouard, C., Plaquevent, J. C., Roques, N. (2000). Design, synthesis and evaluation of a novel class of enantioseletive electrophilic fluorinating agents: Nfluoro ammonium salts of cinchona alkaloids (F-CA-BF4). Org. Lett. 2, 3699-3701.
126. Mohar, B., Baudoux, J., Plaquevent, J. C., Cahard, D. (2001). Electrophilic fluorination mediated by cinchona alkalodis: Highly enantioselective synthesis of alphafluoro-alpha-phenylglycine derivatives. Angew. Chem. Int. Ed. 40, 4214-4216.
127. Shibata, N., Suzuki, E., Asahi, T., Shiro, M. (2001). Enantioselective fluorination mediated by cinchona alkaloid derivatives/Selectfluor combinations: reaction scope and structural information for N-fluorocinchona alkaloids. J. Am. Chem. Soc. 123, 7001-7009.
128. Hamashima, Y., Yagi, K., Takano, H., Tamas, L., Sodeoka, M. (2002). An efficient enantioselective fluorination of various beta-ketoesters catalyed chiral palladium complexes. J. Am. Chem. Soc. 124, 14530-14531.
129. Hamashima, Y., Suzuki, T., Takano, H., Shimura, Y., Sodeoka, M. (2005). Catalytic enantioselective fluorination of oxindoles. J. Am. Chem. Soc. 127, 10164-10165.
130. Hamashima, Y., Suzuki, T., Shimura, Y., Shimizu, T., Umebayashi, N., Tamura, T., Sasamoto, N., Sodeoka, M. (2005). An efficient catalytic enantioselective fluorination of beta-ketophosphonates using chiral palladium complexes. Tetrahedron Lett. 46, 1447-1450.
131. Suzuki, T., Goto, T., Hamashima, Y., Sodeoka, M. (2007). Enantioselective fluorination of tert-butoxycarbonyl lactones and lactams catalyzed by chiral Pd(II)-bisphosphine complexes. J. Org. Chem. 72, 246-250.
132. Hamashima, Y., Suzuki, T., Takano, H., Shimura, Y., Tsuchiya, Y., Moriya, K., Goto. T., Sodeoka, M. (2006). Highly enantioselective fluorination reactions of beta-ketoesters and beta-ketophosphonates catalyzed by chiral palladium complexes. Tetrahedron 62, 7168-7179.
133. Ma, J. A., Cahard, D. (2004). Copper(II) triflate-bis(oxazoline)-catalysed enantioselective electrophilic fluorination of beta-ketoesters. Tetrahedron Asymmetry 15, 1007-1011.
134. Shibata, N., Ishimaru, T., Nagai, T., Kohno, J., Toru, T. (2004). First enantio-flexible fluorination reaction using metal-bis(oxazoline) complexes. Synlett 10, 1703-1706.
135. Shibatomi, K., Tsuzuki, Y., Nakata, S., Sumikawa, Y., Iwasa, S. (2007). Synthesis of axially chiral cyclic amino-substituted 2-(oxazolinyl)pyridine ligands for catalytic asymmetric fluorination of beta-keto esters. Synlett, 551-554.
136. Shibata, N., Kohno, J., Takai, K., Ishimura, T. S., Nakamura, T., Toru, S. K. (2005). Highly enantioselective catalytic fluorination and chlorination reactions of carbonyl compounds of two-point binding. Angew. Chem. Int. Ed. 44, 4204-4207.
137. Reddy, D. S., Shibata, N., Nagai, J., Nakamura, S., Toru, T., Kanemasa, S. (2008). Desymmetrization-like catalytic enantioselective fluorination of malonates and its application to pharmaceutically attractive molecules. Angew. Chem. Int. Ed. 47, 164-168.
138. Paull, D. H., Scerba, M. T., Alden-Danforth, E., Widger, L. R., Lectka, T. (2008). Catalytic, asymmetric alpha-fluorination of acid chlorides: dual metal-ketone enolate activation. J. Am. Chem. Soc. 130, 17260.
139. Hintermann, L., Togni, A. (2000). Catalytic enantioselective fluorination of betaketoesters. Angew. Chem. Int. Ed. 39, 4359.
140. Frantz, R., Hintermann, L., Perseghini, M., Broggini, D., Togni, A. (2003). Titaniumcatalyzed stereoselective geminal heterodihalogenation of beta-ketoesters. Org. Lett. 5, 1709-1712.
141. Marigo, M., Fielenbach, D., Braunton, A., Kjoersgaard, A., Jørgensen, K. A. (2005). Enantioselective formation of stereogenic carbon-fluorine centers by a simple catalytic method. Angew. Chem. Int. Ed. 44, 3703-3706.
142. Steiner, D. D., Mase, N., Barbas, C. F. III. (2005). Direct asymmetric aiphafluorination of aldehydes. Angew. Chem. Int. Ed. 44, 3706-3710.
143. Beeson, T. D., MacMillan, D. W. C. (2005). Enantioselective organocatalytic alphafluorination of aldehydes. J. Am. Chem. Soc. 127, 8826-8828.
144. Jiang, H., Falcicchio, A., Jensen, K. L., Paix ao, M. W., Bertelsen, S., Jørgensen, K. A. (2009). Target-directed organocatalysis: a direct asymmetric catalytic approach to chiral propargylic and allylic fluorides. J. Am. Chem. Soc. 131, 7153-7157.
145. Nagib, D. A., Scott. M. E., MacMillan, D. W. C. (2009). Enantioselective alphatrifluoromethylation of aldehydes via photoredox organocatalysis. J. Am. Chem. Soc. 131, 10875.
146. Allen, A. E., MacMillan, D. W. C. (2010). The productive menger of iodonium salts and organocatalysis: A non-photolytic approach to enantioselective alphatrifluoromethylation of aldehydes. J. Am. Chem. Soc. 132, 4986.